CCL4 and neoplasm: In melanoma, extensive RNA sequencing data has shown that SLC7A1-CCL4 was significantly downregulated in activated CD8+ T cell/DC/proliferating T cell/tumor cell interactions in treated nonresponders during PD-1 inhibitor therapy [46].